These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3606 related articles for article (PubMed ID: 23401870)

  • 1. NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.
    Perampaladas K; Hay N; Rinaldi F; Robertson J; Adam J
    Lancet Oncol; 2013 Jan; 14(1):20-1. PubMed ID: 23401870
    [No Abstract]   [Full Text] [Related]  

  • 2. Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.
    Beale S; Dickson R; Bagust A; Blundell M; Dundar Y; Boland A; Marshall E; Plummer R; Proudlove C
    Pharmacoeconomics; 2013 Dec; 31(12):1121-9. PubMed ID: 24114739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
    Keating GM
    Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
    Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
    Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
    Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma.
    Trudel S; Odolczyk N; Dremaux J; Toffin J; Regnier A; Sevestre H; Zielenkiewicz P; Arnault JP; Gubler B
    BMC Cancer; 2014 Sep; 14():727. PubMed ID: 25265970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
    Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
    Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
    Sosman JA; Kim KB; Schuchter L; Gonzalez R; Pavlick AC; Weber JS; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Hersey P; Kefford R; Lawrence D; Puzanov I; Lewis KD; Amaravadi RK; Chmielowski B; Lawrence HJ; Shyr Y; Ye F; Li J; Nolop KB; Lee RJ; Joe AK; Ribas A
    N Engl J Med; 2012 Feb; 366(8):707-14. PubMed ID: 22356324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
    Deniger DC; Kwong ML; Pasetto A; Dudley ME; Wunderlich JR; Langhan MM; Lee CR; Rosenberg SA
    Clin Cancer Res; 2017 Jan; 23(2):351-362. PubMed ID: 28093487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.
    Brown MP; Long GV
    Asia Pac J Clin Oncol; 2014 Apr; 10 Suppl S3():1-15. PubMed ID: 24712861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
    Kim GH; Levy A; Compoginis G
    J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.
    Maleka A; Åström G; Byström P; Ullenhag GJ
    BMC Cancer; 2016 Aug; 16():634. PubMed ID: 27520988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib-induced bilateral facial palsy.
    Shailesh FN; Singh M; Tiwari U; Hutchins LF
    J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 19. New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.
    Teuma C; Perier-Muzet M; Pelletier S; Nouvier M; Amini-Adl M; Dijoud F; Duru G; Thomas L; Fouque D; Laville M; Dalle S
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):419-26. PubMed ID: 27371224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.
    Busser B; Leccia MT; Gras-Combe G; Bricault I; Templier I; Claeys A; Richard MJ; de Fraipont F; Charles J
    JAMA Dermatol; 2013 Dec; 149(12):1403-6. PubMed ID: 24108467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 181.